CymaBay reports topline 12-week data from an ongoing Phase 2b study of seladelpar
CymaBay Therapeutics announced 12-week topline results from an ongoing 52-week Phase 2b dose-ranging, paired liver biopsy study of seladelpar for treatment of nonalcoholic steatohepatitis. Seladelpar is a potent and selective peroxisome proliferator-activated receptor delta agonist. June 11, 2019